AU2019445706B2 - Fructophilic lactic acid producing bacteria - Google Patents
Fructophilic lactic acid producing bacteria Download PDFInfo
- Publication number
- AU2019445706B2 AU2019445706B2 AU2019445706A AU2019445706A AU2019445706B2 AU 2019445706 B2 AU2019445706 B2 AU 2019445706B2 AU 2019445706 A AU2019445706 A AU 2019445706A AU 2019445706 A AU2019445706 A AU 2019445706A AU 2019445706 B2 AU2019445706 B2 AU 2019445706B2
- Authority
- AU
- Australia
- Prior art keywords
- honey
- fructose
- fructophilic
- probiotic bacteria
- bacillus coagulans
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 title claims abstract description 50
- 241000894006 Bacteria Species 0.000 title claims abstract description 48
- 239000004310 lactic acid Substances 0.000 title claims abstract description 25
- 235000014655 lactic acid Nutrition 0.000 title claims abstract description 25
- 241000193749 Bacillus coagulans Species 0.000 claims abstract description 96
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims abstract description 76
- 239000005715 Fructose Substances 0.000 claims abstract description 68
- 229930091371 Fructose Natural products 0.000 claims abstract description 67
- 238000000034 method Methods 0.000 claims abstract description 24
- 235000013305 food Nutrition 0.000 claims abstract description 14
- 238000002955 isolation Methods 0.000 claims abstract description 12
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 4
- 235000012907 honey Nutrition 0.000 claims description 70
- 229940054340 bacillus coagulans Drugs 0.000 claims description 54
- 239000006041 probiotic Substances 0.000 claims description 37
- 235000018291 probiotics Nutrition 0.000 claims description 37
- 230000000529 probiotic effect Effects 0.000 claims description 34
- 230000012010 growth Effects 0.000 claims description 24
- 229920001817 Agar Polymers 0.000 claims description 19
- 239000008272 agar Substances 0.000 claims description 19
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 15
- 230000001580 bacterial effect Effects 0.000 claims description 15
- 239000000835 fiber Substances 0.000 claims description 15
- 239000000725 suspension Substances 0.000 claims description 15
- 210000000941 bile Anatomy 0.000 claims description 13
- 239000008103 glucose Substances 0.000 claims description 10
- 239000011780 sodium chloride Substances 0.000 claims description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 9
- 150000004666 short chain fatty acids Chemical class 0.000 claims description 9
- 235000020357 syrup Nutrition 0.000 claims description 9
- 239000006188 syrup Substances 0.000 claims description 9
- 108020004465 16S ribosomal RNA Proteins 0.000 claims description 8
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 8
- 239000012138 yeast extract Substances 0.000 claims description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 7
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 7
- 240000001717 Vaccinium macrocarpon Species 0.000 claims description 7
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 claims description 7
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 claims description 7
- 229940041514 candida albicans extract Drugs 0.000 claims description 7
- 235000004634 cranberry Nutrition 0.000 claims description 7
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 7
- 235000021391 short chain fatty acids Nutrition 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 6
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 6
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 6
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 6
- 238000010876 biochemical test Methods 0.000 claims description 6
- 235000013339 cereals Nutrition 0.000 claims description 6
- 239000008121 dextrose Substances 0.000 claims description 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 235000015203 fruit juice Nutrition 0.000 claims description 6
- 235000015243 ice cream Nutrition 0.000 claims description 6
- 239000002054 inoculum Substances 0.000 claims description 6
- 238000012163 sequencing technique Methods 0.000 claims description 6
- 235000013618 yogurt Nutrition 0.000 claims description 6
- 241000208140 Acer Species 0.000 claims description 5
- 240000004246 Agave americana Species 0.000 claims description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 5
- 244000060011 Cocos nucifera Species 0.000 claims description 5
- 235000013162 Cocos nucifera Nutrition 0.000 claims description 5
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 235000016213 coffee Nutrition 0.000 claims description 5
- 235000013353 coffee beverage Nutrition 0.000 claims description 5
- 235000013409 condiments Nutrition 0.000 claims description 5
- 235000009508 confectionery Nutrition 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 235000015897 energy drink Nutrition 0.000 claims description 5
- 235000013611 frozen food Nutrition 0.000 claims description 5
- 235000015110 jellies Nutrition 0.000 claims description 5
- -1 melobiose Chemical compound 0.000 claims description 5
- 235000013379 molasses Nutrition 0.000 claims description 5
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 5
- 235000013324 preserved food Nutrition 0.000 claims description 5
- 239000001917 trigonella foenum graecum l. absolute Substances 0.000 claims description 5
- 241000186427 Cutibacterium acnes Species 0.000 claims description 4
- 244000166102 Eucalyptus leucoxylon Species 0.000 claims description 4
- 108090000854 Oxidoreductases Proteins 0.000 claims description 4
- 102000004316 Oxidoreductases Human genes 0.000 claims description 4
- 241001148132 Salmonella enterica subsp. enterica serovar Abony Species 0.000 claims description 4
- 241000191963 Staphylococcus epidermidis Species 0.000 claims description 4
- 241000194019 Streptococcus mutans Species 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000001963 growth medium Substances 0.000 claims description 4
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims description 4
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- CEQFOVLGLXCDCX-WUKNDPDISA-N methyl red Chemical compound C1=CC(N(C)C)=CC=C1\N=N\C1=CC=CC=C1C(O)=O CEQFOVLGLXCDCX-WUKNDPDISA-N 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 230000001717 pathogenic effect Effects 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- 239000007195 tryptone soya broth Substances 0.000 claims description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 3
- HOVAGTYPODGVJG-UVSYOFPXSA-N (3s,5r)-2-(hydroxymethyl)-6-methoxyoxane-3,4,5-triol Chemical compound COC1OC(CO)[C@@H](O)C(O)[C@H]1O HOVAGTYPODGVJG-UVSYOFPXSA-N 0.000 claims description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 3
- AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 claims description 3
- KUWPCJHYPSUOFW-YBXAARCKSA-N 2-nitrophenyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1[N+]([O-])=O KUWPCJHYPSUOFW-YBXAARCKSA-N 0.000 claims description 3
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- 241000193755 Bacillus cereus Species 0.000 claims description 3
- 102000016938 Catalase Human genes 0.000 claims description 3
- 108010053835 Catalase Proteins 0.000 claims description 3
- WNBCMONIPIJTSB-BGNCJLHMSA-N Cichoriin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1c(O)cc2c(OC(=O)C=C2)c1 WNBCMONIPIJTSB-BGNCJLHMSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 3
- QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 claims description 3
- 239000004386 Erythritol Substances 0.000 claims description 3
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 3
- 241000588724 Escherichia coli Species 0.000 claims description 3
- 206010018910 Haemolysis Diseases 0.000 claims description 3
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 3
- 206010020772 Hypertension Diseases 0.000 claims description 3
- 229920001202 Inulin Polymers 0.000 claims description 3
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 claims description 3
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims description 3
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 claims description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 241000191938 Micrococcus luteus Species 0.000 claims description 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 3
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims description 3
- NGFMICBWJRZIBI-JZRPKSSGSA-N Salicin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1c(CO)cccc1 NGFMICBWJRZIBI-JZRPKSSGSA-N 0.000 claims description 3
- 241000191967 Staphylococcus aureus Species 0.000 claims description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 3
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 claims description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 3
- NGFMICBWJRZIBI-UHFFFAOYSA-N alpha-salicin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UHFFFAOYSA-N 0.000 claims description 3
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 3
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 3
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 3
- 235000019414 erythritol Nutrition 0.000 claims description 3
- 229940009714 erythritol Drugs 0.000 claims description 3
- 229940093496 esculin Drugs 0.000 claims description 3
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 claims description 3
- AWRMZKLXZLNBBK-UHFFFAOYSA-N esculin Natural products OC1OC(COc2cc3C=CC(=O)Oc3cc2O)C(O)C(O)C1O AWRMZKLXZLNBBK-UHFFFAOYSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 claims description 3
- 229930182830 galactose Natural products 0.000 claims description 3
- 210000004211 gastric acid Anatomy 0.000 claims description 3
- 230000008588 hemolysis Effects 0.000 claims description 3
- 230000007062 hydrolysis Effects 0.000 claims description 3
- 238000006460 hydrolysis reaction Methods 0.000 claims description 3
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 3
- 229960000367 inositol Drugs 0.000 claims description 3
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 3
- 229940029339 inulin Drugs 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 229960001855 mannitol Drugs 0.000 claims description 3
- 229940041290 mannose Drugs 0.000 claims description 3
- QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 claims description 3
- HOVAGTYPODGVJG-VEIUFWFVSA-N methyl alpha-D-mannoside Chemical compound CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O HOVAGTYPODGVJG-VEIUFWFVSA-N 0.000 claims description 3
- HOVAGTYPODGVJG-UHFFFAOYSA-N methyl beta-galactoside Natural products COC1OC(CO)C(O)C(O)C1O HOVAGTYPODGVJG-UHFFFAOYSA-N 0.000 claims description 3
- 229940055019 propionibacterium acne Drugs 0.000 claims description 3
- 235000019260 propionic acid Nutrition 0.000 claims description 3
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 3
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims description 3
- HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 claims description 3
- 229940120668 salicin Drugs 0.000 claims description 3
- NGFMICBWJRZIBI-UJPOAAIJSA-N salicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UJPOAAIJSA-N 0.000 claims description 3
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 3
- 230000035939 shock Effects 0.000 claims description 3
- 239000000176 sodium gluconate Substances 0.000 claims description 3
- 235000012207 sodium gluconate Nutrition 0.000 claims description 3
- 229940005574 sodium gluconate Drugs 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 229960002920 sorbitol Drugs 0.000 claims description 3
- 239000000811 xylitol Substances 0.000 claims description 3
- 235000010447 xylitol Nutrition 0.000 claims description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 3
- 229960002675 xylitol Drugs 0.000 claims description 3
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 2
- 235000007575 Calluna vulgaris Nutrition 0.000 claims description 2
- 244000103926 Chamaenerion angustifolium Species 0.000 claims description 2
- 235000006890 Chamerion angustifolium subsp angustifolium Nutrition 0.000 claims description 2
- 235000002278 Chamerion angustifolium subsp circumvagum Nutrition 0.000 claims description 2
- 241000196324 Embryophyta Species 0.000 claims description 2
- 235000004692 Eucalyptus globulus Nutrition 0.000 claims description 2
- 241001074671 Eucalyptus marginata Species 0.000 claims description 2
- 235000019134 Eucalyptus tereticornis Nutrition 0.000 claims description 2
- 241000490229 Eucephalus Species 0.000 claims description 2
- 241000220150 Eucryphia lucida Species 0.000 claims description 2
- 240000008620 Fagopyrum esculentum Species 0.000 claims description 2
- 235000009419 Fagopyrum esculentum Nutrition 0.000 claims description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 2
- 201000001431 Hyperuricemia Diseases 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 206010022489 Insulin Resistance Diseases 0.000 claims description 2
- 240000003553 Leptospermum scoparium Species 0.000 claims description 2
- 235000016887 Leptospermum scoparium Nutrition 0.000 claims description 2
- 240000007472 Leucaena leucocephala Species 0.000 claims description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 claims description 2
- 241000208467 Macadamia Species 0.000 claims description 2
- 241000219071 Malvaceae Species 0.000 claims description 2
- 240000004658 Medicago sativa Species 0.000 claims description 2
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 claims description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 2
- 244000018764 Nyssa sylvatica Species 0.000 claims description 2
- 235000003339 Nyssa sylvatica Nutrition 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 241000372055 Oxydendrum arboreum Species 0.000 claims description 2
- 244000025272 Persea americana Species 0.000 claims description 2
- 235000008673 Persea americana Nutrition 0.000 claims description 2
- 240000001949 Taraxacum officinale Species 0.000 claims description 2
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims description 2
- 240000007313 Tilia cordata Species 0.000 claims description 2
- 241000219793 Trifolium Species 0.000 claims description 2
- 240000000851 Vaccinium corymbosum Species 0.000 claims description 2
- 235000003095 Vaccinium corymbosum Nutrition 0.000 claims description 2
- 235000017537 Vaccinium myrtillus Nutrition 0.000 claims description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 2
- 238000012742 biochemical analysis Methods 0.000 claims description 2
- 235000021014 blueberries Nutrition 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 235000002020 sage Nutrition 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 230000028070 sporulation Effects 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 2
- 238000012512 characterization method Methods 0.000 abstract description 9
- 230000008569 process Effects 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000003833 bile salt Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 238000011534 incubation Methods 0.000 description 8
- 230000000845 anti-microbial effect Effects 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 230000035899 viability Effects 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 108010052444 Oxyrase Proteins 0.000 description 3
- 244000250129 Trigonella foenum graecum Species 0.000 description 3
- 235000001484 Trigonella foenum graecum Nutrition 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 238000002869 basic local alignment search tool Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 210000004051 gastric juice Anatomy 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 235000001019 trigonella foenum-graecum Nutrition 0.000 description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 208000032928 Dyslipidaemia Diseases 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 102000058061 Glucose Transporter Type 4 Human genes 0.000 description 2
- 238000003794 Gram staining Methods 0.000 description 2
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 2
- 241000192132 Leuconostoc Species 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- 108091006300 SLC2A4 Proteins 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- KKEYFWRCBNTPAC-UHFFFAOYSA-N Terephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 description 2
- 239000000370 acceptor Substances 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000003505 mutagenic effect Effects 0.000 description 2
- 231100000243 mutagenic effect Toxicity 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- 238000010953 Ames test Methods 0.000 description 1
- 231100000039 Ames test Toxicity 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 241000301512 Bacillus cereus ATCC 14579 Species 0.000 description 1
- 108010062877 Bacteriocins Proteins 0.000 description 1
- 241000252983 Caecum Species 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 241001360526 Escherichia coli ATCC 25922 Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 description 1
- 241000028295 Fructobacillus ficulneus Species 0.000 description 1
- 241000186777 Fructobacillus fructosus Species 0.000 description 1
- 229920000926 Galactomannan Polymers 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 108091052347 Glucose transporter family Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 244000128833 Mimulus luteus Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 206010028400 Mutagenic effect Diseases 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010080032 Pediocins Proteins 0.000 description 1
- 241000191998 Pediococcus acidilactici Species 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 241000831652 Salinivibrio sharmensis Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 101150014383 adhE gene Proteins 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 108010081577 aldehyde dehydrogenase (NAD(P)+) Proteins 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 235000020246 buffalo milk Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000005574 cross-species transmission Effects 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008151 electrolyte solution Substances 0.000 description 1
- 210000001842 enterocyte Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 230000007773 growth pattern Effects 0.000 description 1
- 235000019534 high fructose corn syrup Nutrition 0.000 description 1
- 239000013029 homogenous suspension Substances 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 230000015784 hyperosmotic salinity response Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 235000015141 kefir Nutrition 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 238000013081 phylogenetic analysis Methods 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 235000020185 raw untreated milk Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 210000004767 rumen Anatomy 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000000276 sedentary effect Effects 0.000 description 1
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 1
- 235000020254 sheep milk Nutrition 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
- C12P7/52—Propionic acid; Butyric acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
- C12P7/54—Acetic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/07—Bacillus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention discloses a novel fructophilic lactic acid producing bacteria Bacillus coagulans strain FF-7 (MTCC 25235) and the process of isolation and characterization of the bacteria. The invention also discloses the biological applications/therapeutic use of fructophilic lactic acid producing bacteria in increased utilization of fructose from food stuff and in the managing disorders related to high fructose intake.
Description
Fructophilic lactic acid producing bacteria
BACKGROUND OF THE INVENTION
Field of the invention
[Para001] The invention in general relates to fructophilic lactic acid producing bacteria. More specifically, the present invention relates to isolation, characterization and biological applications of fructophilic probiotic bacteria Bacillus coagulans.
Description of prior art
[Para002] Probiotics and its importance in health and prevention of many disorders have been already reported. Fructophilic lactic acid bacteria (FLAB) are a special group of lactic acid bacteria which utilizes fructose as a growth substrate. Due to their unique characteristics of poor growth on glucose and preference of oxygen, they are regarded as "unconventional" lactic acid bacteria (LAB). Their unusual growth characteristics are due to an incomplete gene encoding a bifunctional alcohol/acetaldehyde dehydrogenase (adhE). This results in the imbalance of NAD/NADH and the requirement of additional electron acceptors to metabolize glucose. Oxygen, fructose, and pyruvate are used as electron acceptors. FLAB have significantly fewer genes for carbohydrate metabolism than other LAB, especially due to the lack of complete phosphotransferase system (PTS) transporters. FLABs were originally classified as Leuconostoc species and later reclassified as Fmctobacillus species based on their phylogenetic positions and biochemical and morphological characteristics. (Endo A, Okada S. 2008. Reclassification of the genus Leuconostoc and proposals of Fructobacillus fructosus gen. nov., comb nov., Fmctobacillus durionis comb nov., Fructobacillus ficulneus comb. nov. and Fmctobacillus pseudoficulneus comb. nov. Int J Syst Evol Microbiol 58:2195-2205).
[Para003] The metabolism of fructose starts with the enzyme fructase in the liver. The fructose load is converted into lactate in enterocytes and in the liver. Further, excess fructose in the liver is directed toward peripheral tissues, and is taken up by the insulin-dependent glucose transporter, GLUT 4, present on adipose tissue is converted into fatty acids. GLUT 4 is reported to play an important role in the development of fructose-induced hepatic steatosis and dyslipidemia. Further, several fructose induced metabolic disorders are reported like NASH, NAFLD, Dyslipidemia, ectopic lipid deposition in the liver and skeletal muscle, Uric Acid
Metabolism, High Blood Pressure, Mineral Metabolism. (Prasanthi Jegatheesan and Jean-Pascal De Bandt, Fructose and NAFLD: The Multifaceted Aspects of Fructose Metabolism, Nutrients. 2017 Mar; 9(3): 230; Bidwell AJ, Chronic Fructose Ingestion as a Major Health Concern: Is a Sedentary Lifestyle Making It Worse? A Review, Nutrients. 2017 Jun; 9(6): 549). Excessive fructose intake is also associated with increased cardiovascular risk. Increase in fructose intake may also lead to lactic acidosis by excessively decreasing the pH in blood.
[Para004] Probiotics play an important role in metabolizing intestinal fructose. The low dose of fructose that is orally consumed, reach the intestine and is metabolized in the presence of different enzymes and inherent microbiota. However, in the presence of high dose of fructose, the load of fructose spills over from intestine to liver. In order to reduce the spillover of fructose from intestine to liver, probiotics play an important role to convert fructose to SCFAs (Short chain fatty acids).
[Para005] FLABs are isolated from various sources such as fruits and vegetables, human stool culture, natural antimicrobial agent, cheese, kefir grains, dairy and non-dairy products, fermented and raw milk, feces of breast fed infants, lactating milk, sheep, buffalo and cow milk, yogurt, beverages, poultry sources, animal rumen contents, Pengging Duck’s caecum, chicken intestine and fecal samples, chicken feed, enzymes, fermented rice, curd, meat and yeast extracts, glucose and sucrose, human gut, human colonial epithelial cells, human and animal vagina and mouth extraction, diapers of human babies, pineapples wastes, industrial sausages, ice-cream, small intestines of piglets, com slurry, crop and intestinal ducks. The following prior art documents describes the isolation of different FLABs.
1. Akihito Endo, Fructophilic lactic acid bacteria inhabit fructose-rich niches in nature, Microb Ecol Health Dis. 2012; 23
2. Akihito Endo, Shintaro Maeno, Yasuhiro Tanizawa, Wolfgang Kneifel, Masanori Arita, Leon Dicks, Seppo Salminen, Fructophilic Lactic Acid Bacteria, a Unique Group of Fructose Fermenting Microbes, Minireview, Applied and Environmental Microbiology, October 2018 Volume 84 Issue 19 e01290-18
3. Arshad F, Mehmood R, Hussain S, Khan MA, Khan MS (2018) Lactobacilli as Probiotics and their Isolation from Different Sources. Br J Res 5 (3): 43
[Para006] Given that the biological effects of probiotics are strain specific and cannot be generalized to all strains and species (Guidelines for the evaluation of probiotics in food, Joint FAO/WHO Working Group Report on Drafting Guidelines for the Evaluation of Probiotics in Food, London, Ontario, Canada, April 30 and May 1, 2002, See section 3.1 indicating that“The current state of evidence suggests that probiotic effects are strain specific. Strain identity is important to link a strain to a specific health effect as well as to enable accurate surveillance and epidemiological studies.”), there still exists a need to find a superior fructophilic probiotic bacteria with improved biological functions. The present invention solves the above problem by disclosing a novel fructophilic lactic acid bacteria Bacillus coagulans MTCC 25235.
[Para007] It is the principal objective of the invention to disclose a novel fructophilic lactic acid producing bacteria Bacillus coagulans MTCC 25235 and its process of isolation.
[Para008] It is another objective of the invention to disclose the production of short chain fatty acid by fructophilic lactic acid producing bacteria Bacillus coagulans MTCC 25235.
[Para009] It is yet another objective of the invention to disclose the anti-microbial effects of fructophilic lactic acid producing bacteria Bacillus coagulans MTCC 25235.
[Para0010] The present invention solves the above mentioned objectives and provides further related advantages.
Deposit of Biological Material
[Para0011] The deposit of biological material Bacillus coagulans strain FF7 bearing accession number MTCC 25235, mentioned in the instant application has been made on 28th February 2019 at Microbial Type Culture Collection & Gene Bank (MTCC), CSIR-Institute of Microbial Technology, Sector 39-A, Chandigarh - 160036, India.
Summary of the Invention
[Para0012] The present invention discloses the fructophilic lactic acid producing bacteria. The invention further discloses the process of isolation, characterization and biological applications/therapeutic use of fructophilic lactic acid producing bacteria.
[Para0013] Other features and advantages of the present invention will become apparent from the following more detailed description, which illustrate, by way of example, the principle of the invention.
BRIEF DESCRIPTION OF DRAWINGS
[Para0014] The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the office upon request and payment of the necessary fee.
[Para0015] FIG. 1A, IB, 1C and ID shows the phase contrast microscopic image (x 1000 magnification) of Bacillus coagulans MTCC 25235 (FIG. 1A), wet mount of cells with the spores (FIG. IB), Gram staining of vegetative cells (FIG. 1C), Spore staining of sporulated cells and (FIG. ID), colony grown on GYE agar plate.
[Para0016] FIG. 2 shows graphical representation of comparison of growth pattern of Bacillus coagulans FF7, MTCC 25235 and B. coagulans ATCC 31284 in presence of fructose and dextrose as carbon source. Values are mean (±SD) from three independent determinations.
[Para0017] FIG. 3 shows graphical representation of utilization of fructose by Bacillus coagulans MTCC FF7, 25235 after 24 h of incubation in presence of media and fructose rich foods (Honey, fruit juice). Values are mean (±SD) from three independent determinations.
[Para0018] FIG. 4 shows phylogenetic tree based on the sequence of 16S rRNA showing the relative positions of Bacillus coagulans FF7.
[Para0019] FIG. 5 shows effect of different pH on the growth of B. coagulans FF7, MTCC 25235 and B. coagulans ATCC 31284, optimum pH for the growth was found to be pH 7.5 and pH 6.5 respectively. Values are mean (±SD) from three independent determinations.
[Para0020] FIG. 6 shows graphical representation of effects of different temperatures on the growth of B. coagulans MTCC FF7, 25235 and B. coagulans ATCC 31284. Values are mean (±SD) from three independent determinations.
[Para0021] FIG. 7 shows Effect of GIT hostile conditions on the viability of B. coagulans MTCC 25235 after gastric treatment in an in-vitro experiment mimicking invivo conditions. Sterile saline was taken as untreated control.
[Para0022] FIG.8 shows BSH activity of Bacillus coagulans MTCC 25235. (FIG. 8A) Determination using soft MRS agar supplemented with ox bile (0.3%, w/v) and CaC03 (0.3%, w/v) and MRS agar without bile salts served as the negative control (FIG. 8B). Hollow zones suggest the BSH activity of B. coagulans MTCC 25235.
[Para0023] FIG. 9 shows graphical representation of the survival of Bacillus coagulans MTCC FF7, 25235 at various pH values (1.5-8.0) in gastric juice buffer. The values are expressed in
Log 10 spores/g. Data represent the mean and standard deviations (±SD) of two different experiments performed.
[Para0024] FIG. 10 shows graphical representation of in-vitro effect of ox bile salt on the growth of B. coagulans FF7, MTCC 25235 and B. coagulans ATCC 31284. The overnight grown fresh culture of B. coagulans MTCC 25235 and B. coagulans ATCC 31284 were inoculated in MRS broth with (0.1, 0.3, 0.4, 0.5, 0.6, 0.8, 0.9 and 1%, w/v) and without ox bile salt (%, w/v). Values are mean (±SD) from three independent determinations.
[Para0025] FIG. 11 shows graphical presentation of production of L-Lactic acid by B. coagulans FF7, MTCC 25235 in presence of two standardized preparations equivalent to 6x 109 (preparation 1) and 15xl09 cfu/g (preparation 2) were studied. Values are mean (±SD) from three independent determinations.
[Para0026] FIG. 12A, 12B and 12 C shows graphical presentation of Acetic FIG. 12A, butyric FIG. 12 B and propionic acid FIG. 12C production from the Bacillus coagulans MTCC 25235 while fermenting fructose, FOS, cranberry seed fibre, fenugreek seeds fibre. Samples were collected after 4, 8, 12, 18 and 24 h of fermentation. Values are average mean of triplicate performed at two different occasions and represented in mg/g.
[Para0027] FIG. 13 shows graphical presentation of Viability of B. coagulans MTCC 25235 during the storage at temperature 40 ± 2 °C with RH 60 % ± 5 %. Two standardized preparations equivalent to 15x 109 (preparation 1) and 6xl09 cfu/g (preparation 2) were studied. Average means of spore viable counts are expressed in log 10 cfu/g. Each time point represents the mean Logic standard deviations (±SD) of three different experiments performed in duplicate.
DESCRIPTION OF THE MOST PREFERRED EMBODIMENTS
[Para0028] In the most preferred embodiment, the present invention discloses a method for isolating and identifying novel fructose utilizing probiotic bacteria from honey, comprising step of:
a) Mixing honey with saline in the ratio of 1:10 w/v to obtain a suspension;
b) Thoroughly mixing the suspension of step a) and providing heat shock at 50-70°C for 30 minutes for selective isolation of spores;
c) Isolating the bacterial colonies by incubating 1-2 ml of the suspension from step b) in suitable culture media containing fructose for 48 hrs at 35-37°C;
d) Purifying bacterial isolates by selecting and incubating morphologically distinct colonies in a suitable media containing fructose as carbon source;
e) Identifying the bacterial strain by biochemical analysis and 16S rRNA sequencing as Bacillus coagulans strain FF7 bearing accession no. MTCC 25235.
[Para0029] In a related aspect, the honey is selected from the group comprising, but not limited to, raw honey, filtered honey, acacia honey, alfalfa honey, aster honey, avocado honey, basswood honey, beechwood honey, blueberry honey, bluegum honey, buckwheat honey, clover honey, dandelion honey, eucalyptus honey, fireweed honey, heather honey, ironbark honey, jarrah honey, leatherwood honey, linden honey, macadamia honey, manuka honey, orangeblossom honey, pinetree honey, sourwood honey, sage honey, and tupelo honey. In another related aspect, the culture media is selected from the group comprising MRS (De Man, Rogosa and Sharpe agar), GYA (Glucose Yeast Extract Agar), TSB (Tryptone Soya Broth), Sporulation media and Mueller Hinton Agar.
[Para0030] In another related aspect, the isolated probiotic strain returns positive for biochemical tests catalase, oxidase, methyl red, voges proskauers, lactose, xylose, maltose, fructose, dextrose, galactose, raffinose, trehalose, melobiose, sucrose, arabinose, mannose, inulin, sodium gluconate, salicin, sorbitol, mannitol, arabitol, methyl glucoside, rhamnose, cellobiose, ONPG, esculin hydrolysis and negative for biochemical tests sorbose malonate utilization, citrate utilization, xylitol, methyl mannoside, melezitose, erythritol, adonitol, inositol, dulcitol, glycerol, blood hemolysis, citrate and indole.
[Para0031] In another preferred embodiment, the invention discloses a novel probiotic bacteria of the genus Bacillus, isolated from honey for increased utilization of fructose from foods rich in fructose. In another related aspect, the fructophilic probiotic bacterium is Gram positive. In yet another aspect, optimum pH and temperature recorded for the growth of fructophilic bacteria is 7.5 and 40 °C respectively. In another aspect, the fructophilic probiotic bacteria is bile tolerant, gastric acid resistance and produces lactic acid. In a related aspect, the fructophilic probiotic bacteria is Bacillus coagulans. In yet another related embodiment, the Bacillus coagulans strain is Bacillus coagulans MTCC 25235. In a related aspect, the foods rich in fructose are selected from the group comprising high fructose corn syrup, honey, Agave, Maple syrup, Coconut sugar, Palm sugar, Molasses, Soda, Candies, sweetened yogurt, frozen foods, canned foods, cereals, fruit juices, coffee creamer, jams and jellies, energy drinks, condiments, ice cream. In a related
aspect, the fructophilic probiotic bacteria is used for the therapeutic management of disorders related to high fructose intake. In a related aspect, diseases related to high fructose intake are selected from the group comprising, but not limited, obesity, non-alcoholic steatohepatitis (NASH), insulin resistance, metabolic syndrome, cardio-vascular complications, diabetes, hyperlipidemia, hypertension, inflammation and hyperuricemia. In another related aspect, the fructophilic probiotic bacteria is present in the form of an inoculum, freeze-dried powder, fine powder, tablet, capsule, suspension, solution, emulsion, gummy, chewable or edible foods and administered as a stand-alone or in combination with foods rich in fructose selected from the group comprising high fructose com syrup, honey, Agave, Maple syrup, Coconut sugar, Palm sugar, Molasses, Soda, Candies, sweetened yogurt, frozen foods, canned foods, cereals, fruit juices, coffee creamer, jams and jellies, energy drinks, condiments, ice cream.
[Para0032] In yet another preferred embodiment, the invention discloses a method of inhibiting pathogenic microbes said method comprising step of bringing to contact said microbes with the fructophilic probiotic bacteria Bacillus coagulans MTCC 25235. In a related aspect, the pathogenic microbes are selected from the group comprising Salmonella abony, Micrococcus luteus, Escherichia coli, Pseudomonas aeruginosa, Bacillus cereus, Propionibacterium acnes, Streptococcus mutans, Staphylococcus aureus, Staphylococcus epidermidis.
[Para0033] In another preferred embodiment, the invention discloses a method of producing short chain fatty acids by culturing the fructophilic probiotic bacteria Bacillus coagulans MTCC 25235 along with plant fibers selected from the group consisting of fructose, fenugreek seed fibers, cranberry seed fibers, fructooligosaccharides (FOS).
[Para0034] The specific examples included herein below illustrate the aforesaid most preferred embodiments of the present invention.
[Para0035] EXAMPLES
[Para0036] Example 1: Isolation and identification of fructophilic bacteria
[Para0037] Methods
[Para0038] Raw unfiltered honey was used in this study to isolate the spore forming fructophilic lactic acid bacteria. For the isolation of fructophilic bacteria, de Man, Rogosa and Sharpe (MRS) (dextrose replaced by fructose) was used in this study (table 1).
[Para0039] Table 1: Media composition
[Para0040] One gm of unfiltered raw honey was taken into the test tubes containing 10 ml of saline. This was mixed well and heat shock was given at 70°C for 30 minutes for selective isolation of spores. Isolation of bacteria was carried out by adding 1 ml of above sample from each dilution onto the MRS agar plates containing fructose. Plates were further incubated at 37°C for 48 h. After incubation, morphologically distinct colonies were picked up for further testing and purification of bacterial isolates. Bacillus coagulans MTCC 25235 was isolated and streaked on other MRS agar plate containing fructose as carbon source.
[Para0041] Biochemical characterization of fructophilic bacteria
[Para0042] Bacterial isolates were grown in de Man, Rogosa and Sharpe Agar (MRSA) for 24 h at 37°C. Bacterial inoculums were prepared by picking 1 to 3 well isolated colonies and a homogenous suspension in sterile saline was prepared. The density of suspension was ³ 0.5 OD at 620 nm. This inoculum (50 ml) of was used and test was performed as per the kit manufacturer’s instructions (HiMedia, Mumbai, India). Biochemical characterization of Bacillus coagulans MTCC 25235 and B. coagulans ATCC 31284 was performed by the method described (Majeed, M., Nagabhushanam, K., Natarajan, S., Sivakumar, A., Eshuis-de Ruiter, T., Booij-Veurink, J., Janine Booij-Veurink, Ynte P. de Vries, Ali, F. (2016); Evaluation of genetic
and phenotypic consistency of Bacillus coagulans MTCC 5856: A commercial probiotic strain. World Journal of Microbiology & Biotechnology, 32,60). HiCarbohydrate™ Kit (code-KB009) was procured from HiMedia, Mumbai, India and tests were performed as per the manufacturer’s instructions. Bacterial suspension of Bacillus coagulans MTCC 25235 and B. coagulans ATCC 31284 was prepared as mentioned in above section. Further, IMViC (indole, methyl red, Voges Proskauer, Citrate utilization) test, oxidase and Gram staining of and B. coagulans ATCC 31280 were performed as per the method Majeed et al, (2016); (Cappucino G and Natalie Sherman. Microbiology: A Laboratory manual 5th edition. 1998).
[Para0043] 16S rDNA sequencing
[Para0044] 16S rDNA sequencing Genomic DNA of the B. coagulans MTCC 5856 was prepared as previously described by (William J. Bruno, Nicholas D. Socci, and Aaron L. Halpem (2000). Weighted Neighbor Joining: A Likelihood-Based Approach to Distance-Based Phytogeny Reconstruction, Mol. Biol. Evol. 17 (1): 189-197). A fragment of the 16S rDNA gene was sequenced using an ABI 3500 genetic analyser automated DNA sequencer as described earlier (Heyrman and Swings 2001). The sequencing primers used were 5-
AGHGTBTGHTCMTGNCTCAS 3 (Forward Primer) and 5-
TRCGGYTMCCTTGTWHCGACTH - 3 (Reverse Primer). The amplified DNA fragment of approximately 1.5 kb separated on a 1 % agarose gel and purified by using Qiagen spin columns. The purified fragment was used directly for DNA sequencing. This sequence was used in a BLAST search (http://blast.ncbi.nlm.nih.gov/Blast.cgi).
[Para0045] Growth conditions of Bacillus coagulans MTCC 25235
[Para0046] The optimization of growth conditions for Bacillus coagulans MTCC 25235 was analyzed for different temperature and pH. MRSB media was prepared and adjusted pH to 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5 and 8.0 with 2 N HC1 and 2N NaOH. Overnight grown culture (1%, v/v) inoculated to pH adjusted media and incubated for 24h in a shaking incubator at 120 tpm. Growth was monitored at every six hour interval of time by measuring absorbance at 600 run using spectrophotometer (Shimadzu Corporation, Kyoto, Japan). MRSB media was prepared adjusted pH to 6.5 and inoculated with overnight grown culture (1%, v/v). Further, flasks were incubated for 24h in shaking incubator at 120 rpm at different temperatures (20, 30, 37, 40, 50 and 60°C). Growth was monitored at every six hour interval of time by measuring absorbance at 600 nm using spectrophotometer (Shimadzu Corporation, Kyoto, Japan).
[Para0047] Results
[Para0048] Identification of fructophilic bacteria
[Para0049] The spores of Bacillus coagulans MTCC 25235 were ellipsoidal terminal spores (FIG 1A) and vegetative cells were Gram positive rod shaped as indicated in Gram’s stain (FIG 1B). Colonies from B. coagulans MTCC 25235 were grown on media, yielding uniform, 1-3 mm in diameter, white to cream, smooth colonies that contain vegetative rod shaped cells (FIG. 1C and D). The growth of the isolated bacteria was better in fructose rich media rather than dextrose rich media (FIG. 2), indicating its fructophilic nature and fructose utilization potential when comp ared to other Bacillus coagulans strains. The growth of the bacterial was also tested in fructose rich food stuff and showed a deduction in the fructose content (FIG. 3) implying that the bacterium utilizes fructose as a carbon source for its growth and development. Thus, the bacterium can be used in managing and preventing disorders related to high fructose intake by utilizing the excess fructose in the food stuff for its metabolism The bacteria can be administered as a stand alone or in combination with foods rich in fructose which include high fructose com syrup, honey, Agave, Maple syrup, Coconut sugar, Palm sugar, Molasses, Soda, Candies, sweetened yogurt, frozen foods, canned foods, cereals, fruit juices, coffee creamer, jams and jellies, energy drinks, condiments, ice cream (Braverman J, List of Foods high in fructose, https://www.livestrong.com/article/30454-list-foods-high-fructose/· accessed 3rd May 2019)
[Para0050] Biochemical characterization
[Para0051] Biochemical characterization of Bacillus coagulans MTCC 25235 and B. coagulans ATCC 31284 was performed by the method described (Majeed, M., Nagabhushanam, K., Natarajan, S., Sivakumar, A., Eshuis-de Ruiter, T., Booij-Veurink, J., Janine Booij-Veurink, Ynte P. de Vries, Ali, F. (2016); Evaluation of genetic and phenotypic consistency of Bacillus coagulans MTCC 5856: A commercial probiotic strain. World Journal of Microbiology & Biotechnology, 32,60). The results were compared with commercial strain B. coagulans ATTCC 3128 and tabulated in Table 2.
[Para0052] Table 2: Biochemical characterization of B. coagulans ATTCC 3128 and Bacillus coagulans MTCC 25235
[Para0053] The results indicated that the isolated probiotic strain is positive for biochemical tests catalase, oxidase, methyl red, voges proskauers, lactose, xylose, maltose, fructose, dextrose, galactose, raffinose, trehalose, melobiose, sucrose, melobiose, arabinose, mannose, inulin, sodium gluconate, salicin, sorbitol, mannitol, arabitol, methyl glucoside, rhamnose, cellobiose, ONPG, esculin hydrolysis and negative for biochemical tests sorbose malonate utilization, citrate utilization, xylitol, methyl mannoside, melezitose, erythritol, adonitol, inositol, dulcitol, glycerol, blood hemolysis, citrate and indole.
[Para0054] 16S rDNA sequencing
[Para0055] The bacterial 16S rDNA was sequenced and the sequence information (SEQ ID) was obtained as below:
A BLAST (Basic local alignment search tool) search was performed with the above sequence and results of the first 10 alignment sequences are tabulated in table 3.
Table 3: Alignment view using combination of NCBI GenBank - Distribution of 10 Blast Hits on the Query Sequence
[Para0056] The results indicated that the isolated organism is a new strain of Bacillus coagulans having 98.96% identity with Bacillus coagulans strain 55-LR4. The results of the phylogenetic analysis also indicated that the organism is a new strain of Bacillus coagulans (FIG.4)
[Para0057] Optimum of the growth conditions for fructophilic bacteria
[Para0058] The optimum pH and temperature recorded for the growth of fructophilic bacteria was 7.5 and 40 °C respectively (FIG.5 and FIG. 6)
[Para0059] Example 2: In vitro probiotic evaluation of Bacillus coagulans MTCC 25235 [Para0060] Resistance to gastric acid
[Para0061] The survival of Bacillus coagulans MTCC 25235 spores was studied by addition of 1 ml of suspension into 100 ml of a sterile electrolyte solution (6.2 g/L NaCl, 2.2 g/L KC1, 0.22 g/L CaC12, and 1.2 g/L NaHCOS) containing 0.01% lysozyme (Sigma-Aldrich) and 0.3% pepsin (Sigma- Aldrich) and incubated for 5 min. Further, pH was adjusted to 1.5, 3, 4, 5, 6, 7 and 8 (adjusted using 1 N NaOH and 1 N HC1). Incubation temperature was monitored to 37°C for 4h. One ml of sample was withdrawn at different time intervals at 0, 1.0, 2.0, 3.0 and 4.0 h. After incubation, serial dilution was done in sterile saline (0.89 % w/v) and the viable count was enumerated by plating on glucose yeast extract agar (HiMedia). Experiments were performed in triplicate at two different occasions.
[Para0062] Bile salt tolerance
[Para0063] Bile tolerance of Bacillus coagulans MTCC 25235 cells was determined by the method described earlier (Gilliland et al. 1984; Hyronimus et al. 2000). MRS broth (HiMedia) was inoculated with approximately 106 cfu mL-1 of Bacillus coagulans MTCC 25235 overnight grown culture and then supplemented with (0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.5 and 2.0 %, w/v) bile salt and without bile salt as control in the experiment. Samples were incubated for 24 h at 37 °C with shaking at 120 ipm. Growth in control (no bile) and test cultures at different concentrations of bile was monitored hourly by measuring absorbance at 600 nm using spectrophotometer (Shimadzu Corporation, Kyoto, Japan).
[Para0064] Production of lactic acid
[Para0065] Lactic acid production by Bacillus coagulans MTCC 25235 was estimated by using a Megazyme kit. A loopful of an overnight grown culture of Bacillus coagulans MTCC 25235 was added to glucose yeast extract broth (HiMedia) and incubated at 37 °C for 18 h with 120 rpm. After incubation, the broth was filtered through 0.22 micron (Sartorius, India) and analyzed for lactic acid content by using Megazyme kit (K-DLATE 10/04) as per instructions (Megazyme International Ireland, IDA Business Park, Wicklow, Ireland). GYE media was taken as blank in the assay.
[Para0066] Simulated gastric juice tolerance
[Para0067] The survival of Bacillus coagulans MTCC 25235 spores was studied to represent buccal digestion conditions. One mL of the suspension of Bacillus coagulans MTCC 25235 was
subjected to stimulated salivary juice contents consist of KC1 (0.8946 g/l), CO (NH2)2 (0.1981 g/L), Na2S04 (0.5681 g/L), NaHCO3 (1.680 g/L), NaH2P04 (0.8878 g/L), pH adjusted to 6.8± 0.2 and incubated at 37°C for 5 min. Further, simulated gastric juice was prepared by adding 9 g/L of sodium chloride and 3 g/L of pepsin (Sigma-Aldrich, St. Louis, MO, USA) and then the pH was adjusted to aseptically 3.0 ± 0.2 by using 2 N HCI. Samples were further incubated at 37°C for 3 h with low r.p.m. After 3 h of incubation, pH was adjusted aseptically to 7.0 using 2 N NaOH. Ox bile (5 g/L) this was further incubated at 37 °C for 24 h. After final step of the simulated digestion process, samples were collected and evaluated for the spore survival of Bacillus coagulans MTCC 25235 was enumerated by serial dilution method using glucose yeast extract agar media (HiMedia) (FIG. 7).
[Para0068] Antibiotic resistance pattern
[Para0069] MIC was determined as per the guidelines of Clinical and Laboratory Standards Institute (CLSI 2012). Bacillus coagulans MTCC 25235 suspensions were prepared by suspending 18 h grown bacterial culture in sterile normal saline (0.89% NaCl wt/vol; Himedia, Mumbai India). The turbidity of the bacterial suspension was adjusted to 0.5 McFarland standards (equivalent to 1.5 x 108 colony forming units (CFU)/ml). The antibiotics stock solutions were prepared as per CLSI guidelines and 2-fold serial dilutions were prepared in broth medium (glucose yeast extract acetate broth [GYEA, HiMedia, Mumbai India for Bacillus coagulans MTCC 25235 and Mueller Hinton Broth [MHB, Difco Laboratories, Detroit, Mich USA] for S. aureus) in 100 ml volume in 96-well U bottom microtiter plates (BD Labware, NJ USA). The above-mentioned bacterial suspension was further diluted in the MHB and 100 ml volume of this diluted inoculum was added to each well of the plate resulting in the final inoculum of 5 x 105 CFU/ml in the well and the final concentration of antibiotics ranged from 0.0078 to 4 mg/ml. S. aureus ATCC 6538 was used as reference culture in this study. The plates were incubated at 37°C for 24 h and were visually read for the absence or presence of turbidity. The minimum concentration of the compound concentration showing no turbidity was recorded as MIC.
[Para0070] AMES TEST
[Para0071] The data of the experiment suggested that the B. coagulans MTCC 25235 spores did not increase the number of revertants in five Salmonella strains (TA98, TA100, TA102, TA1535 and TA1537), compared with their negative controls, either absence or presence of the
S9 metabolic activation system. Further, no dose- dependent mutagenic effects were caused by the B. coagulans MTCC 25235 spores (up to 5000 mg/plate). B. coagulans MTC 25235 spores did not show any mutagenic activity under the experimental conditions.
[Para0072] BSH activity
[Para0073] Bacillus coagulans MTCC 25235 growth was observed on an agar plate containing ox bile and calcium carbonate, which indicates its tolerance against ox bile and the presence of BSH activity. There was 19±2 mm clear zone in the soft agar plate as shown in (FIG. 8A and 8B) which indicated the presence of BSH activity.
[Para0074] Antimicrobial activity against human pathogens
[Para0075] The antimicrobial activity was performed by a well diffusion assay as previously described with minor modifications (Cintas LM, Rodriguez JM, Fernandez MF, Sletten K, Nes IF, Hernandez PE, Holo H (1995) Isolation and characterization of pediocin L50, a new bacteriocin from Pediococcus acidilactici with a broad inhibitory spectrum. Appl Environ Microbiol 61:2643-2648). Briefly, a 5 mL lawn of soft (0.7 % agar) glucose yeast extract (HiMedia, India), containing 106 cfu mL-1) of the indicator strains (S. epidermidis ATCC 14990, S. mutans MTCC 1943, S. aureus ATCC 29213, B. cereus ATCC 14579, P. acnes ATCC 11827, E. coli ATCC 25922, P. aeruginosa ATCC 9027, M. luteus NCIM 216 and S. abony NCIM 2257) was poured on top of an enriched hard (1.5 % agar) tryptic soya agar (HiMedia, India). A loopful of overnight grown culture B. coagulans MTCC 25325 was added to MRS media and incubated for 24 h at 37 °C with 120 rpm. After 24 h, the culture was centrifuged (10,000x9g) to remove the cells and the supernatant was collected, concentrated tenfold by lyophilization and filter-sterilized through a 0.22 micron filter (Sartorius, India). Concentrated supernatant (50 pL) was added to 6-mm wells punched in the solidified bi-layer agar. Plates were kept in the refrigerator (4 ± 2 °C) for 5 h to allow the sample to diffuse into the agar and subsequently incubated at 37 °C for 18-20 h. After incubation, the zone of inhibition was measured and recorded in mm
[Para0076] Production of short chain fatty acids
[Para0077] The in vitro fermentation with the Bacillus coagulans MTCC 25235 was carried out by following method described by McBumey and Thompson (1987) with some modifications. Briefly, 2.0 g of fructose, fenugreek seeds, cranberry seed fiber, FOS, were added to 100 ml of
demineralised water. The pH was adjusted to 7.0 ± 0.2 and autoclaved at 121°C for 20 min. After sterilization, oxygen reducing enzyme Oxyrase (Oxyrase® for Broth, Oxyrase, Inc, OH, USA) was added to each flask, to induce anaerobic conditions. Five percent of overnight grown Bacillus coagulans MTCC 25235 culture was inoculated to all the flasks and incubated at 37°C with gentle shaken rpm for 24 h. The bottles were tightly closed and sealed with parafilm to maintain anaerobic conditions generated by the enzyme supplement. The pH values at 0 h of incubation and after fermentation (24 h) were also recorded. One ml of copper sulphate (10 g/L) was added to each sample to inhibit further microbial growth (Sigma-Aldrich, St. Louis, MO, USA). Further, 5.0 ml of samples were added to 5 ml of distilled water and pH was adjusted to 1.5 using 3 M H2SO4. 10 ml of chilled diethyl ether (-20°C) was added to samples and then vortex for 1 minute. Sodium chloride was added and then centrifuged at 3000x g for 10 minutes. After centrifugation, organic layer was separated and transferred to the flesh vial. This was used to quantify SCFAs. The SCFA standards were purchased from Sigma-Aldrich (St. Louis, MO, USA) and similarly processed. SCFA production (acetate, propionate and butyrate) was measured by gas chromatography (GC) with the use of a Agilent technologies 6890N gas chromatograph (Stevens Creek Blvd Santa Clara, CA, USA) containing a DB-FFAP (Terephthalic acid modified poly ethylene Glycol) column. The column temperature was 200°C. The injector and detector port temperatures were 250°C. The carrier gas was N2 at a flow rate of 1.0 ml/min. SCFA standards were purchased from Sigma-Aldrich (St. Louis, MO, USA). SCFA (Acetate, propionate and butyrate) concentrations were expressed in mg/gram of galactomannan from fenugreek seeds.
[Para0078] Result
[Para0079] Resistance to gastric add
[Para0080] There was no significant difference (2-5%) in spore count at pH 3 to pH 8.0 in comparison to the initial spore count up to 4 h of the study (FIG. 9). However, 0.44 and 2.036 logic reduction was observed at pH 1.5 in 1 and 4 h respectively. Results of the study confirmed the stability of Bacillus coagulans MTCC 25235 spores in acidic as well as alkaline pH conditions.
[Para0081] Bile tolerance test
[Para0082] Bacillus coagulans MTCC 25235 growth was observed on the agar plate containing bile salt (1 % w/v) which indicated its tolerance against bile salt. Further, bile tolerance assay
was performed by supplementing (0.1-2.0%) ox bile to the MRS broth in different flask. Bacillus coagulans MTCC 25235 growth observed in presence and absence of ox bile up to 2%, w/v. Whereas, growth of B. coagulans ATCC 31284 was found in 0.8% w/v (FIG. 10). Similarly, there was no significant difference in the viability of Bacillus coagulans MTCC 25235 and B. coagulans ATCC 31284 in the presence and absence of bile salt.
[Para0083] Production of lactic acid
[Para0084] Lactic acid production by Bacillus coagulans MTCC 25235 was estimated by using a Megazyme kit. The total lactic acid produced by Bacillus coagulans MTCC 25235 was 4.487 g/L. L-form of lactic acid was 4.12 g/L. Whereas, D-form of lactic acid Bacillus coagulans MTCC 25235 is 0.367 g/L. (FIG. 11)
[Para0085] Antibiotic resistance
[Para0086] MIC results of clindamycin, kanamycin, ampicillin, streptomycin, vancomycin, erythromycin, gentamicin, tetracycline and chloramphenicol against the Bacillus coagulans MTCC 25235 and S. aureus ATCC 6538 is given in table 4. All the antibiotics tested showed a MIC range of 0.0078 to 1.0 mg/ml against Bacillus coagulans MTCC 25235. All tested antibiotics exhibited a MIC range of 0.031 to 2 mg/ml against S. aureus ATCC 6538.
[Para0087] Table 4: Minimum inhibitory concentrations of antibiotics against Bacillus coagulans MTCC 25235 cultures and S. aureus ATCC 6538
[Para0088] Antimicrobial activity
The antimicrobial activity of B. coagulans MTCC 25235 was evaluated. Anti-microbial activity was determined by well diffusion assay as described by Cintas et al. (1995). The results indicated that the probiotic bacteria is an effective antimicrobial agent against Salmonella abony, Micrococcus luteus, Escherichia coli, Pseudomonas aeruginosa, Bacillus cereus, Propionibacterium acnes, Streptococcus mutans, Staphylococcus aureus, Staphylococcus epidermidis.
[Para0089] Table 4: Antimicrobial activity of B. coagulans MTCC 25235 against tested bacteria
Data represent the mean ± SD of three independent experiments performed in triplicate
[Para0090] Short chain fatty acid production
[Para0091] The results of the analysis are presented in FIG. 12A, 12B and 12C. The production of acetic acid was high for B. coagulans MTCC 25235 with FOS, followed by fenugreek seed fibers, cranberry fibers and fructose (FIG. 12 A). Similarly, the production of butyric acid was high for B. coagulans MTCC 25235 with fructose, followed by FOS, fenugreek seed fibers and cranberry fibers (FIG. 12 B). The production of propionic acid was similar for B.
coagulans MTCC 25235 cultured with fructose, FOS and cranberry seed fibers and lower for fenugreek seed fibers (FIG. 12 C).
[Para0092] Storage and viability
[Para0093] Two standardized preparations equivalent to 15x 109 (preparation 1) and 6x109 cfu/g (preparation 2) were studied. B. coagulans MTCC 25235 showed enhanced viability during the storage at temperature 40 ± 2 °C with RH 60 % ± 5 % (FIG. 13)
[Para0094] Other modifications and variations to the invention will be apparent to those skilled in the art from the foregoing disclosure and teachings. Thus, while only certain embodiments of the invention have been specifically described herein, it will be apparent that numerous modifications may be made thereto without departing from the spirit and scope of the invention.
The scope of the invention is to be interpreted only in conjunction with the appended claims.
Claims (18)
1. A method for isolating and identifying novel fructose utilizing probiotic bacteria from honey, comprising step of:
f) Mixing honey with saline in the ratio of 1 : 10 w/v to obtain a suspension;
g) Thoroughly mixing the suspension of step a) and providing heat shock at 50-70°C for 30 minutes for selective isolation of spores;
h) Isolating the bacterial colonies by incubating 1-2 ml of the suspension from step b) in suitable culture media containing fructose for 48 hrs at 35-37°C;
i) Purifying bacterial isolates by selecting and incubating morphologically distinct colonies in a suitable media containing fructose as carbon source;
j) Identifying the bacterial strain by biochemical analysis and 16S rRNA sequencing as Bacillus coagulans strain FF7 bearing accession no. MTCC 25235.
2. The method as in claim 1, wherein the honey is selected from the group comprising, raw honey, filtered honey, acacia honey, alfalfa honey, aster honey, avocado honey, basswood honey, beechwood honey, blueberry honey, bluegum honey, buckwheat honey, clover honey, dandelion honey, eucalyptus honey, fireweed honey, heather honey, iroribark honey, jarrah honey, leatherwood honey, linden honey, macadamia honey, manuka honey, orangeblossom honey, pinetree honey, sourwood honey, sage honey, and tupelo honey.
3. The method as in claim 1, wherein the culture media is selected from the group comprising MRS (De Man, Rogosa and Sharpe agar), GY A (Glucose Yeast Extract Agar), TSB (Tryptone Soya Broth), Sporulation media and Mueller Hinton Agar.
4. The method as in claim 1, wherein the isolated probiotic strain returns positive for biochemical tests catalase, oxidase, methyl red, voges proskauers, lactose, xylose, maltose, fructose, dextrose, galactose, raffinose, trehalose, melobiose, sucrose, arabinose, mannose, inulin, sodium gluconate, salicin, sorbitol, mannitol, arabitol, methyl glucoside, rhamnose, cellobiose, ONPG, esculin hydrolysis and negative for biochemical tests sorbose malonate utilization, citrate utilization, xylitol, methyl mannoside,
melezitose, erythritol, adonitol, inositol, dulcitol, glycerol, blood hemolysis, citrate and indole.
5. A fructophilic probiotic bacteria of the genus Bacillus, isolated from honey for increased utilization of fructose from foods rich in fructose.
6. The probiotic bacteria as claimed in claim 5, wherein the said fructophilic probiotic bacterium is Gram positive.
7. The probiotic bacteria as claimed in claim 5, wherein the optimum pH and temperature for the growth of fructophilic bacteria is 7.5 and 40 °C respectively.
8. The probiotic bacteria as claimed in claim 5, wherein the said fructophilic probiotic bacteria is bile tolerant, gastric acid resistance and produces lactic acid.
9. The probiotic bacteria as claimed in claim 5, wherein the said fructophilic probiotic bacterium is Bacillus coagulans.
10. The probiotic bacteria as claimed in claim 5, wherein the Bacillus coagulans strain is Bacillus coagulans MTCC 25235.
11. The probiotic bacteria as claimed in claim 5, wherein the foods rich in fructose are selected from the group comprising high fructose com syrup, honey, Agave, Maple syrup, Coconut sugar, Palm sugar, Molasses, Soda, Candies, sweetened yogurt, frozen foods, canned foods, cereals, fruit juices, coffee creamer, jams and jellies, energy drinks, condiments, ice cream.
12. The probiotic bacteria as claimed in claim 5, wherein the said fructophilic probiotic bacteria is used for the therapeutic management of disorders related to high fructose intake.
13. The disorders related to high fructose intake as in claim 12, are selected from the group comprising, obesity, non-alcoholic steatohepatitis (NASH), insulin resistance, metabolic syndrome, cardio-vascular complications, diabetes, hyperlipidemia, hypertension, inflammation and hyperuricemia.
14. The probiotic bacteria as claimed in claim 5, wherein the said fructophilic probiotic bacteria is present in the form of an inoculum, freeze-dried powder, fine powder, tablet, capsule, suspension, solution, emulsion, gummy, chewable or edible foods and administered as a stand alone or in combination with foods rich in fructose selected from the group comprising high fructose com syrup, honey, Agave, Maple syrup, Coconut
sugar, Palm sugar, Molasses, Soda, Candies, sweetened yogurt, frozen foods, canned foods, cereals, fruit juices, coffee creamer, jams and jellies, energy drinks, condiments, ice cream.
15. A method of inhibiting pathogenic microbes said method comprising step of bringing to contact said microbes with the fructophilic probiotic bacteria Bacillus coagulans MTCC 25235.
16. The method as in claim 15, wherein the pathogenic microbes are selected from the group comprising Salmonella abony, Micrococcus luteus, Escherichia coli, Pseudomonas aeruginosa, Bacillus cereus, Propionibacterium acnes, Streptococcus mutans, Staphylococcus aureus, Staphylococcus epidermidis.
17. A method of producing short chain fatty acids by culturing the fructophilic probiotic bacteria Bacillus coagulans MTCC 25235 along with plant fibers selected from the group consisting of fructose, fenugreek seed fibers, cranberry seed fibers, fructooligosaccharides (FOS).
18. The method as in claim 17, wherein the short chain fatty acids are selected from the group comprising acetic acid, butyric acid and propionic acid.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2019/031965 WO2020231397A1 (en) | 2019-05-13 | 2019-05-13 | Fructophilic lactic acid producing bacteria |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2019445706A1 AU2019445706A1 (en) | 2022-01-06 |
AU2019445706B2 true AU2019445706B2 (en) | 2024-04-18 |
Family
ID=73289609
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2019445706A Active AU2019445706B2 (en) | 2019-05-13 | 2019-05-13 | Fructophilic lactic acid producing bacteria |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP3969606A4 (en) |
JP (1) | JP7469332B2 (en) |
KR (1) | KR20220007660A (en) |
CN (1) | CN114207107A (en) |
AU (1) | AU2019445706B2 (en) |
BR (1) | BR112021022916A2 (en) |
CA (1) | CA3140038A1 (en) |
MX (1) | MX2021013902A (en) |
WO (1) | WO2020231397A1 (en) |
ZA (1) | ZA202110214B (en) |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7767203B2 (en) * | 1998-08-07 | 2010-08-03 | Ganeden Biotech, Inc. | Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption |
JP4888622B2 (en) * | 2001-06-04 | 2012-02-29 | キユーピー株式会社 | Oligonucleotide and method for detecting batylscore glance using the same as primer |
CA2669431C (en) * | 2005-11-16 | 2019-04-23 | Pro Natura Gesellschaft Fuer Gesunde Ernaehrung Mbh | Agent for use in the case of fructose intolerance |
CN100473720C (en) * | 2007-10-18 | 2009-04-01 | 中国科学院微生物研究所 | Method for producing L-lactic acid and coagulate bacillus cereus special for the same |
JP2010148402A (en) * | 2008-12-24 | 2010-07-08 | Toyo Shokuhin Kenkyusho | Method for detecting bacillus coagulans and oligonucleotide for detection |
CN101914465B (en) * | 2010-05-20 | 2012-10-03 | 上海交通大学 | Bacillus coagulans for preparing L-lactic acid and application method thereof |
BR112013015255A2 (en) * | 2010-12-17 | 2016-09-13 | Gervais Danone Sa | lactococcus lactis strains for use in improving digestive condition |
JP5892580B2 (en) * | 2011-04-14 | 2016-03-23 | 国立大学法人 琉球大学 | Method for producing novel lactic acid bacteria and L-lactic acid, and food and medicine containing lactic acid bacteria |
US9371548B2 (en) * | 2011-04-14 | 2016-06-21 | Industrial Technology Research Institute | Method for producing butyric acid, butanol and butyrate ester |
US9596861B2 (en) * | 2013-12-24 | 2017-03-21 | Sami Labs Limited | Method of producing partially purified extracellular metabolite products from Bacillus coagulans and biological applications thereof |
JP6486612B2 (en) * | 2014-05-27 | 2019-03-20 | 株式会社山田養蜂場本社 | Lactic acid bacteria having antiallergic action and uses thereof |
WO2016033572A1 (en) * | 2014-08-29 | 2016-03-03 | Muhammed Majeed | Process for enhancing the viable counts of lactic acid bacteria and useful compositions thereof |
PL3240553T3 (en) * | 2016-01-07 | 2020-08-24 | Sami Labs Limited | Process for the therapeutic management of diarrhea predominant irritable bowel syndrome using bacillus |
-
2019
- 2019-05-13 CA CA3140038A patent/CA3140038A1/en active Pending
- 2019-05-13 WO PCT/US2019/031965 patent/WO2020231397A1/en unknown
- 2019-05-13 JP JP2021568485A patent/JP7469332B2/en active Active
- 2019-05-13 AU AU2019445706A patent/AU2019445706B2/en active Active
- 2019-05-13 CN CN201980097794.9A patent/CN114207107A/en active Pending
- 2019-05-13 EP EP19929028.9A patent/EP3969606A4/en active Pending
- 2019-05-13 BR BR112021022916A patent/BR112021022916A2/en unknown
- 2019-05-13 KR KR1020217040516A patent/KR20220007660A/en unknown
- 2019-05-13 MX MX2021013902A patent/MX2021013902A/en unknown
-
2021
- 2021-12-09 ZA ZA2021/10214A patent/ZA202110214B/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3969606A4 (en) | 2023-01-11 |
AU2019445706A1 (en) | 2022-01-06 |
JP2022536252A (en) | 2022-08-15 |
JP7469332B2 (en) | 2024-04-16 |
BR112021022916A2 (en) | 2022-01-18 |
KR20220007660A (en) | 2022-01-18 |
EP3969606A1 (en) | 2022-03-23 |
WO2020231397A1 (en) | 2020-11-19 |
MX2021013902A (en) | 2022-03-11 |
ZA202110214B (en) | 2023-06-28 |
CN114207107A (en) | 2022-03-18 |
CA3140038A1 (en) | 2020-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11116806B2 (en) | Composite probiotic lactic acid bacteria powder and preparation method and use thereof | |
Lavermicocca et al. | Study of adhesion and survival of lactobacilli and bifidobacteria on table olives with the aim of formulating a new probiotic food | |
JP3046303B1 (en) | Helicobacter pylori eradication food and drink | |
JP2002534113A (en) | Bifidobacterium in the treatment of inflammatory diseases | |
WO2002070670A1 (en) | Novel lactobacillus reuteri useful as probiotics | |
CN103079580A (en) | Use of lactobacilli inhibiting gas producing coliform bacteria isolated from infants affected by colic | |
KR101868517B1 (en) | Lactobacillus fermentum PL9119 with biofunctional activities and high heat stability as a probiotic without antibiotic resistance | |
AU2011302135A1 (en) | Bacillus subtilis isolate from corn | |
JP4456160B2 (en) | Novel lactic acid strains and their use | |
Sadrani et al. | Screening of potential probiotic Lactobacillus strains isolated from fermented foods, fruits and of human origin | |
CN114231473A (en) | Probiotic lactobacillus plantarum and application thereof in preparation of low-salt fermented meat food | |
EP1840205A1 (en) | Bifidobacterium lactis 668 strain used for ar a component for food products, starters, medicinal and cosmetic agents | |
JP6033290B2 (en) | A novel Lactobacillus plantarum isolated from tea leaves | |
CN117143767A (en) | Breast milk-derived fermented lactobacillus mucilaginosus MSJK0025 capable of regulating intestinal flora and application thereof | |
US12077749B2 (en) | Bifidobacterium longum subsp. infantis with fimbriae and applications thereof | |
CN112029676B (en) | Probiotic composition beneficial to improving immunity and application thereof | |
US11197898B2 (en) | Fructophilic lactic acid producing bacteria | |
WO2020017390A1 (en) | Lactic acid bacterium, natural immune activating agent derived from lactic acid bacterium, and preventive/therapeutic drug for infection and food or beverage | |
AU2019445706B2 (en) | Fructophilic lactic acid producing bacteria | |
JP2006180836A (en) | Lactic acid bacterium controlling infection with food poisoning bacterium, fermentation product, food and medicine composition containing the same | |
KR100503570B1 (en) | Novel Pediococcus pentosaceus EROM101 having immune enhancement, anticancer and antibacterial activities | |
US20220118032A1 (en) | Fructophilic lactic acid producing bacteria | |
Zavišić et al. | Characterisation and preliminary lipid-lowering evaluation of Lactobacillus isolated from a traditional Serbian dairy product | |
RU2735717C1 (en) | Bifidobacterium bifidum strain used as a probiotic | |
de Vasconcelos Medeiros et al. | Cereus jamacaru DC.(mandacaru) fruit as a source of lactic acid bacteria with in vitro probiotic-related characteristics and its protective effects on Pediococcus pentosaceus during lyophilization and refrigeration storage |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) |